Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy ImmuCell Corporation stock

Own ImmuCell Corporation stock in just a few minutes.

Fact checked

ImmuCell Corporation is a biotechnology business based in the US. ImmuCell Corporation shares (ICCC) are listed on the NASDAQ and all prices are listed in US Dollars. ImmuCell Corporation employs 53 staff and has a trailing 12-month revenue of around USD$15.2 million.

How to buy shares in ImmuCell Corporation

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for ImmuCell Corporation. Find the stock by name or ticker symbol: ICCC. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until ImmuCell Corporation reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of ImmuCell Corporation, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of ImmuCell Corporation. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

ImmuCell Corporation share price

Use our graph to track the performance of ICCC stocks over time.

ImmuCell Corporation shares at a glance

Information last updated 2020-12-27.
52-week rangeUSD$3.7 - USD$6.51
50-day moving average USD$5.9453
200-day moving average USD$5.5411
Wall St. target priceUSD$14
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.3

Buy ImmuCell Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy ImmuCell Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is ImmuCell Corporation under- or over-valued?

Valuing ImmuCell Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of ImmuCell Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

ImmuCell Corporation's EBITDA

ImmuCell Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$1.3 million.

The EBITDA is a measure of a ImmuCell Corporation's overall financial performance and is widely used to measure a its profitability.

ImmuCell Corporation financials

Revenue TTM USD$15.2 million
Gross profit TTM USD$6.7 million
Return on assets TTM -1.57%
Return on equity TTM -5.32%
Profit margin -9.99%
Book value $3.885
Market capitalisation USD$45.1 million

TTM: trailing 12 months

Shorting ImmuCell Corporation shares

There are currently 5,720 ImmuCell Corporation shares held short by investors – that's known as ImmuCell Corporation's "short interest". This figure is 68.3% up from 3,398 last month.

There are a few different ways that this level of interest in shorting ImmuCell Corporation shares can be evaluated.

ImmuCell Corporation's "short interest ratio" (SIR)

ImmuCell Corporation's "short interest ratio" (SIR) is the quantity of ImmuCell Corporation shares currently shorted divided by the average quantity of ImmuCell Corporation shares traded daily (recently around 8937.5). ImmuCell Corporation's SIR currently stands at 0.64. In other words for every 100,000 ImmuCell Corporation shares traded daily on the market, roughly 640 shares are currently held short.

However ImmuCell Corporation's short interest can also be evaluated against the total number of ImmuCell Corporation shares, or, against the total number of tradable ImmuCell Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ImmuCell Corporation's short interest could be expressed as 0% of the outstanding shares (for every 100,000 ImmuCell Corporation shares in existence, roughly 0 shares are currently held short) or 0.0024% of the tradable shares (for every 100,000 tradable ImmuCell Corporation shares, roughly 2 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against ImmuCell Corporation.

Find out more about how you can short ImmuCell Corporation stock.

ImmuCell Corporation share dividends

We're not expecting ImmuCell Corporation to pay a dividend over the next 12 months.

Have ImmuCell Corporation's shares ever split?

ImmuCell Corporation's shares were split on a 1:100 basis on 25 July 1990. So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your ImmuCell Corporation shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for ImmuCell Corporation shares which in turn could have impacted ImmuCell Corporation's share price.

ImmuCell Corporation share price volatility

Over the last 12 months, ImmuCell Corporation's shares have ranged in value from as little as $3.7 up to $6.51. A popular way to gauge a stock's volatility is its "beta".

ICCC.US volatility(beta: 1.15)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ImmuCell Corporation's is 1.1533. This would suggest that ImmuCell Corporation's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

ImmuCell Corporation overview

ImmuCell Corporation, an animal health company, acquires, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. The company sells its products through animal health distributors. ImmuCell Corporation was founded in 1982 and is headquartered in Portland, Maine.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site